Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
The hospital chain aggressively embarks on digitisation and is e-health ready
The MoU was signed on World Organ Donation Day which falls on August 13
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Subscribe To Our Newsletter & Stay Updated
